20, 2 daily Bollinger bands are closing in indicating a big move in direction. Last week a bearish trend reversal with 2 black crows was spotted on the pond. Today a breakdown in support was confirmed. Yes I'm having a verklempt moment. Too much market rain lately may breech the Gern pond's beaver dam.
CONFIRMED breakdown below 2.99, no support in area just below.
Type: True breakdown from Double support.
I hope not!
...obstruction of true process can only go so far. Eventually too many empty bottles of wine will lead to abnormal liver function tests which under the FDA's own Hy's law it must put an end to.( not to mention their following low)
Mr Mugoo the answer lies in what MF stage diagnosis these patients were treated with IMET. All patients in the MAYO were advanced 3rd & 4th stage patients with no other options left. IMET so to speak brought them back from the brink. Knowing this it stands to reason expanding treatment for MF patients with 1ST & 2ND stage could lead to much earlier CR's and a much higher % of remission success. Given the recent PMF LF reversibility data submitted to the FDA by the MAYO perhaps wider indications for PMF, ET & PV are possible eliminating other less effective current treatments that carry greater negative side effects, like RUX.
Zacks needed to post this headline today. Ugly market low vol. opp. fur our friendly hedge fund to run over some critters for a road kill barbecue bonanza.
....who needs a windbag pipeline full of hot air when you're holding the 'Holy Grail' of cancer drugs?
Enough with management's ineptness. With a moot class action shadow lurking in the wings Chippy is not going out in public with a bunch of unsubstantiated forward looking statements. We have no idea what is going on behind the scene and his next move must be one of substance based on clinical trials to further the development of IMET. The MAYO has given him the ammo he needs to fire this through to the next stage. WAIT FUR IT!
with a 8mil share spike in the morning this is much more than a few over zealous day traders jumping in on hype. The article merely underlined the fundamentals at play.
INCYE wouldn't require combo therapy if they had a drug that could offer clinical remissions like IMET, soon to become complete remissions without toxic side effects like their lead candidate RUX presently does. With a $20 decline in INCY's SP the current value of GERN should be $20. After phase II or fast tracked BAT designation it will be much higher.
Always buy when vol. and price start to shoot up. Same thing happened the Monday of June 9, vol spiked SP started moving up and 3 days later news of the partial FDA hold release on MAYO's clinical trials.
Sentiment: Strong Buy
Glad to hear John's continued improvement, especially the reversibility stats supporting normal LFT. Belated birthday wishes to him. His birthday presence is a present for us all, even though I missed out on a piece of the cake. ;=3)
POTENTIAL X EVENTS;
could be several.
1) An expedited approval pathway in the works for MF trials soon to be announced. IMET fills this void and current need perfectly
2) A partnership announcement
3) A new multi-centred MF phase II trial continuation application submission
I bet you wish you could muster up a brain fart once I a while Maine. Look at the advantage you have wearing a colostomy bag.....you don't ever have to leave your computer desk for washroom breaks and your on line message posting pay becomes a continuous stream. Not to mention your daily production can easily be discarded in biohazard container at the end of each day.
INCY's pipeline consists of several indications for Jakafi, basically an anti inflammatory cancer treatment, none of which offer cancer remissions. Slight improvements in the condition with arm's length lists of serious side effects. The other 'breakfast serial' additives under the INC group have so far been dismal failures in their clinical trials which may explain the company's SP drop from $70 down to $50. Sound familiar? IMET on the other hand has given several people with 3rd & 4th stage MF clinical remissions and as far as we know still holding this bench mark. This is a huge accomplishment, regardless of how insignificant you make it seem.
From my brief experience with GERN my only observation from your comments Maine is to denigrate and belittle any poster ID that brings depth and insight to the board. Seems like your 'incyte' is more in promoting GERN's competitor than that of GERN's Holy Grail.
And I thought it was because I mentioned all the ill gotten earnings hedge fund owners made last year. George Soros $4Bil, David T e p per $3.5Bil And then David Cohen's insider trading fraud fine of $1.8Bil compared to his $2.3Bil earnings. Seems stiff until you realize the other $11Bil he's accumulated came from similar shady trading deals and or activity.
As Irish has implied the MAYO clinical hold on MF has been lifted allowing phase II to proceed.
As to the entire clinical hold being lifted on PV and ET trials your guess is as good as mine.
If all the above mentioned posters were the same multiple I-Der and removed from this board there would be no one left for you to mock, belittle or to discredit with your disparaging comments when the long or short of it is that you have no clue yourself as evidenced from your lack of any contribution of substance to this board.
We must share the same ID Maine as I too have used the term "brain fart" most likely in reference to one of your useless posts bfr.